Therapeutic Advances in Medical Oncology · 2019 · 35 citations · 16 references
MedicineImmunologyOncologyImmunotherapyMeta-analysisMetastasisCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune CheckpointsKidney CancerRenal Cell CarcinomaImmune Checkpoint Inhibitor ResponseImmune Checkpoint Inhibitor TherapyImmune Checkpoint ReceptorsImmune Checkpoint ResistanceMetastatic Renal Cell Carcinoma TherapyPd-l1 BlockadePrognostic Subgroup AnalysisProgrammed Death-ligand 1 Biomarker
Background: The aim of this study was to perform a literature-based meta-analysis to assess the efficacy of the novel immune checkpoint inhibitors (ICIs) in first-line metastatic renal cell carcinoma (RCC), focusing on the predictive role of PD-L1 expression. Methods: The primary outcome was overall survival, and secondary outcomes were progression-free survival (PFS) and objective response. We planned a subgroup analysis for overall survival according to PD-L1 status. Results: Five studies were included in the analysis for a total of 4063 cases. Overall survival was greater in PD-L1 positive tumours (HR = 0.49, 95% CI: 0.36–0.67; p < 0.001). The pooled analysis of the unselected cases showed a statistically significative improvement in PFS with the use of ICIs (HR = 0.85, 95% CI: 0.72–0.99; p = 0.04) and we found a greater PFS benefit (HR = 0.65, 95% CI: 0.57–0.74; p < 0.001) in patients with PD-L1 positive tumours. Conclusions: This study supports the efficacy of ICIs and, although a significant clinical benefit has been reported in PD-L1 negative patients, a greater efficacy of ICIs was observed in PD-L1 positive patients. More prospective randomized studies are needed to clarify the role of PDL-1 status in metastatic RCC treated with ICIs.
16
Meta-analysis in clinical trials
Rebecca DerSimonian, Nan M. Laird · Controlled Clinical Trials · 1986 · 39.3K citations
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
The Combination of Estimates from Different Experiments
William G. Cochran · Biometrics · 1954 · 5.4K citations